TEVA (STOCKS)
Teva Pharmaceutical Industries Limited American Depositary Shares
$34.880000
+0.510000 (+1.48%)
Prev close: $34.370000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Generic
- CEO
- Richard Francis
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $39,727.14M
- Employees
- 35,686
- P/E (TTM)
- 28.13
- P/B (TTM)
- 5.00
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.96 | $0.69 | +0.2671 | +38.55% |
|
Sep 2025 (Q3)
|
$0.78 | $0.67 | +0.1105 | +16.50% |
|
Jun 2025 (Q2)
|
$0.66 | $0.63 | +0.0293 | +4.65% |
|
Mar 2025 (Q1)
|
$0.52 | $0.49 | +0.0287 | +5.84% |
Financial Statements
| Revenues | $17.26B |
| Benefits Costs and Expenses | $16.04B |
| Cost Of Revenue | $8.32B |
| Costs And Expenses | $16.04B |
| Gross Profit | $8.94B |
| Nonoperating Income/Loss | -$934.00M |
| Operating Expenses | $6.78B |
| Depreciation and Amortization | $1.00B |
| Other Operating Expenses | $5.78B |
| Operating Income/Loss | $2.16B |
| Income/Loss Before Equity Method Investments | $1.22B |
| Income/Loss From Continuing Operations After Tax | $1.40B |
| Income/Loss From Continuing Operations Before Tax | $1.22B |
| Income/Loss From Equity Method Investments | $15.00M |
| Income Tax Expense/Benefit | -$180.00M |
| Interest Expense, Operating | $916.00M |
| Net Income/Loss | $1.42B |
| Net Income/Loss Attributable To Noncontrolling Interest | $7.00M |
| Net Income/Loss Attributable To Parent | $1.41B |
| Net Income/Loss Available To Common Stockholders, Basic | $1.41B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $1.23 |
| Diluted Earnings Per Share | $1.21 |
| Basic Average Shares | 1,145,000,000 |
| Diluted Average Shares | 1,163,000,000 |
| Assets | $40.75B |
| Current Assets | $13.95B |
| Inventory | $3.18B |
| Prepaid Expenses | $1.12B |
| Other Current Assets | $9.65B |
| Noncurrent Assets | $26.80B |
| Fixed Assets | $4.08B |
| Other Non-current Assets | $22.72B |
| Liabilities | $32.83B |
| Current Liabilities | $13.46B |
| Accounts Payable | $225.00M |
| Wages | $739.00M |
| Other Current Liabilities | $12.49B |
| Noncurrent Liabilities | $19.38B |
| Redeemable Noncontrolling Interest | $0.00 |
| Equity | $7.91B |
| Equity Attributable To Noncontrolling Interest | $4.00M |
| Equity Attributable To Parent | $7.91B |
| Temporary Equity | $0.00 |
| Liabilities And Equity | $40.75B |
| Net Cash Flow From Operating Activities | $1.65B |
| Net Cash Flow From Operating Activities, Continuing | $1.65B |
| Net Cash Flow From Investing Activities | $737.00M |
| Net Cash Flow From Investing Activities, Continuing | $737.00M |
| Net Cash Flow From Financing Activities | -$2.15B |
| Net Cash Flow From Financing Activities, Continuing | -$2.15B |
| Exchange Gains/Losses | $21.00M |
| Net Cash Flow | $256.00M |
| Net Cash Flow, Continuing | $235.00M |
| Comprehensive Income/Loss | $2.20B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $34.00M |
| Comprehensive Income/Loss Attributable To Parent | $2.17B |
| Other Comprehensive Income/Loss | $784.00M |
| Other Comprehensive Income/Loss Attributable To Parent | $757.00M |